alexa 36 Months Outcome Of Drug-eluting Balloon Angioplasty In The Femoropopliteal And Infrapopliteal Arteries
ISSN: 2155-9880

Journal of Clinical & Experimental Cardiology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

World Heart Congress
May 22- 24, 2017 Osaka, Japan

Berkan Ozpak
Corlu State Hospital, Turkey
Posters & Accepted Abstracts: J Clin Exp Cardiolog
DOI: 10.4172/2155-9880-C1-069
Abstract
Drug-eluting balloons (DEBs), which allow the homogeneous delivery of an anti-proliferative drug (e.g., paclitaxel) to the arterial vessel wall without leaving residual prosthetic material, have become an effective strategy for treating lesions of the femoropopliteal arteries. In contrast, the outcomes of medical therapy in below-the-knee (BTK) region are often unsatisfactory, and early, aggressive percutaneous revascularization with the aim of ensuring direct flow to the foot is increasingly considered a first-line strategy. On the basis of this background, we designed a prospective study to evaluate the performance and outcomes of DEB therapy for infrapopliteal atherosclerotic disease, using the primary patency rate at 12, 24 and 36 months. Patients with infrapopliteal PAD were enrolled in this independent, non-industry-supported, prospective study. From August 2010 to December 2013, 307 arteries of 123 patients were revascularized. The patients’ demographic characteristics (e.g., age, sex, ankle–brachial index [ABI], Rutherford class, hyperlipidemia, hypertension, coronary artery disease, smoking, diabetes, and calcification) were documented. The ABI after 36 months was significantly higher than the baseline ABI (p<0.001), and the Rutherford classification after 36 months was significantly lower than the baseline Rutherford classification (p<0.001; Table).The median baseline Rutherford classifications was 4 (3.0-4.0). Both Rutherford reduction and ABI improvement were statistically significant (p<0.001). ABI improvement was 59.3% (38 of 64) at 36 months (p=0.032). Limb salvage was achieved in 73.6% (28 of 38) of the critical limb ischemia (CLI) patients and complete wound healing occurred in 67.8% (19 of 28) of patients with Rutherford category 5. Given the unavoidable disease progression within and outside the treated arterial lesion, DEBs represent an attractive alternative without limiting future treatment options, in comparison to first-line revascularization strategies.
Biography

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords